Skip to main content
  • Cumulative Intracranial Tumor Volume and Number of Brain Metastasis as Predictors of Developing New Lesions after Stereotactic Radiosurgery for Brain Metastasis.

    Final Number:
    366

    Authors:
    Mayur Sharma MD MCh; Xuefei Jia MS; Gene H. Barnett MD; Michael A. Vogelbaum MD, PhD; Samuel T. Chao MD; John H. Suh; Erin Murphy; Jennifer Yu; Lilyana Angelov MD, FRCS(C); Alireza M Mohammadi MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: The aim of our study was to identify risk factors associated with distant radiographic progression in patients undergoing stereotactic radiosurgery (SRS) for brain metastases (BM).

    Methods: Following IRB approval, data of 1427 patients (4283 BM lesions) who were treated using SRS at Cleveland Clinic from 2000-2012 were collected. Distant tumor progression at 3 and 6 months were the primary end points and correlated to patient related variables. Logistic regression and competing risk models were used for data analysis.

    Results: The median number of targets was 2 (range 1-17) with 45% of patients having a single lesion. 45.9% of patient had lesions >2cm in size and median total intracranial tumor volume was 2.6 cc (range 0.03-83cc). Overall, 4% and 9% of patients had local progression in 3 and 6 months, respectively. Distant progression was observed in 10% and 19% at 3 and 6 months. Patients with 2-4 target lesions were more likely to develop new lesions compared to those with single lesions at 3 months (OR: 0.84, P<0.001) and 6 months (OR: 0.87, 0=0.014). Similarly, patients with 5-10 target lesions for SRS were more likely to develop new lesions at both 3 and 6 months compared to those with 2-4 lesions (OR: 0.83, CI: 0.40-0.85 and OR:0.85, CI: 0.45-0.86 respectively, p<0.05). Higher number of lesions (>5), cumulative intracranial tumor volume (CITV) (= 2.75 cc), radiographic progression after SRS, type of SRS (boost versus upfront and salvage) and tumor pathology (radio resistant) were independent predictors of distant tumor progression following SRS.

    Conclusions: Number of target lesions (>5) and CITV (= 2.75 cc) are both independent predictors of distant tumor progression following SRS for BM at first and second follow up (3 and 6 months after SRS). Radio sensitivity of tumor and addition of WBRT are also predictors of distant intracranial progression.

    Patient Care: The results of our study can be used in tailoring the follow up of the patients following SRS for Brain metastases (BM).

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Identify various risk factors associated with distant radiographic tumor progression in patients undergoing SRS for BM.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy